We need just a little extra information

    As a VIPPS accredited pharmacy licensed and/or authorized in all 50 states, pharmacy regulation requires us to ask for your shipping zip code.

    OstiMax (Deracoxib) Chewable Tablets for Dogs 100mg

    Product ID: **V*OSTIMAX100

    OstiMax (Deracoxib) Chewable Tablets for Dogs 100mg

    Price: Select Quantity Below

    Prescription Required In Stock
    - Select Quantity (Tablets) -
    15  Tablets
    $46.05
    Select
    30  Tablets
    $83.40(Save 9%)
    Select
    45  Tablets
    $124.20(Save 10%)
    Select
    60  Tablets
    $162.60(Save 11%)
    Select
    90  Tablets
    $234.90(Save 14%)
    Select
    Custom Tablet Quantity
    Select
    Add To My Cart (AutoReorder)

    Add To My Cart (One-Time Purchase)

    Product Summary

    This product requires a valid prescription for shipment, please note that HealthWarehouse.com may not accept prescriptions faxed or emailed by patients.
    • VETERINARY PRESCRIPTION REQUIRED
    • This drug is not approved for human use.

    For oral use in dogs only


    CAUTION:

    Federal law restricts this drug to use by or on the order of a licensed veterinarian.


    DESCRIPTION:

    OstiMax™ (deracoxib) is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID) of the coxib class. OstiMax tablets are round, biconvex, chewable tablets that contain deracoxib formulated with beefy flavoring.


    USES:

    OstiMax Chewable Tablets (deracoxib) are indicated for the control of post-operative pain and inflammation associated with orthopedic (bone) and dental surgery in dogs and for the control of pain and inflammation (soreness) associated with osteoarthritis in dogs. See package insert for complete product details.


    DOSAGE AND ADMINISTRATION:

    Postoperative Orthopedic Pain and Inflammation: 1.4 - 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. Inaccurate dosing may result in adverse drug events (see Adverse Reactions, Animal Safety and Post-Approval Experience). Postoperative Dental Pain and Inflammation: OstiMax Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with dental surgery in dogs. Dosage and Administration: Postoperative Dental Pain and Inflammation: 0.45 - 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days. The first dose should be given approximately 1 hour prior to dental surgery and subsequent doses should be given daily for up to two additional treatments. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. Inaccurate dosing may result in adverse drug events (see Adverse Reactions, Animal Safety, and Post-Approval Experience). Since deracoxib chewable tablets bioavailability is greatest when taken with food, postprandial administration is preferable. However, deracoxib chewable tablets have been shown to be effective under both fed and fasted conditions; therefore, they may be administered in the fasted state if necessary. For postoperative orthopedic and dental pain, administer OstiMax tablets prior to the procedure. Tablets are scored and dosage should be calculated in half-tablet increments. In clinical practice it is recommended to adjust the individual patient dose while continuing to monitor the dog’s status until a minimum effective dose has been reached.


    CONTRAINDICATIONS:

    Dogs with known hypersensitivity to deracoxib should not receive OstiMax.


    WARNINGS:

    Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For use in dogs only. Do not use in cats. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. Inaccurate dosing may result in adverse drug events (see Adverse Reactions, Animal Safety, and Post-Approval Experience). All dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID is recommended. Owners should be advised to observe for signs of potential drug toxicity (see Adverse Reactions, Animal Safety and Post-Approval Experience) and be given an “Information for Dog Owners” Sheet.


    All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered. Owners should be advised to observe for signs of potential drug toxicity.


    PRECAUTIONS:

    Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. Inaccurate dosing may result in adverse drug events (see Adverse Reactions, Animal Safety, and Post-Approval Experience). Since NSAIDs possess the potential to produce gastrointestinal ulceration and/or perforation, concomitant use of OstiMax tablets with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. As a class, NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. The following collective group of clinical signs has been reported with some serious gastrointestinal events, in decreasing order of reported frequency: anorexia, tachycardia, tachypnea, pyrexia, ascites, pale mucous membranes, dyspnea. In some cases, circulatory shock, collapse and cardiac arrest have also been reported. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Plasma levels of deracoxib may increase in a greater than dose-proportional fashion above 8 mg/kg/day. Deracoxib tablets have been safely used during field studies in conjunction with other common medications, including heartworm preventatives, anthelmintics, anesthetics, pre-anesthetic medications, and antibiotics. If additional pain medication is needed after a daily dose of OstiMax tablets, a non-NSAID/non-corticosteroid class of analgesic may be necessary. It is not known whether dogs with a history of hypersensitivity to sulfonamide drugs will exhibit hypersensitivity to OstiMax tablets. The safe use of deracoxib tablets in dogs younger than 4 months of age, dogs used for breeding, or in pregnant or lactating dogs has not been evaluated. NSAIDs may inhibit the prostaglandins which maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Appropriate monitoring procedures should be employed during all surgical procedures. The use of parenteral fluids during surgery should be considered to decrease potential renal complications when using NSAIDs perioperatively. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. The use of concomitantly protein-bound drugs with deracoxib tablets has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of deracoxib tablets has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.


    STORAGE:

    Store at controlled room temperature 15°-30°C (59°-86°F).

    Healthcare savings, delivered

    Our Happy Customers

    • “Awesome, service. Very fast, placed my order Friday received it Monday morning... I'm a very happy customer Thanks ”

      Alex L.  Santa Ana, CA.

    • “Wonderful service! Received my order today without any delays. Thanks.”

      Lynda T. 

    • “So far I am so pleased. Your prices are outstanding . I will be sending all my prescriptions. Fast and easy too. Thanks”

      David S. 

    Accredited & Certified In All 50 States

    HealthWarehouse.com has been accredited by the National Association of Boards of Pharmacy® (NABP®) for Digital Pharmacy and is licensed / accredited with all 50 State Boards of Pharmacy. Based in Florence, Kentucky, Healthwarehouse.com is the leader in Digital Pharmacy and a pioneer in affordable healthcare, providing incredible patient services since 2007.

    Digital Pharmacy